Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Birchview Capital, LP
Form 13F · Q2 2026

Birchview Capital, LP

CIK 1618205Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$214M
Reported book value
73
Positions
12
Quarters on record
Top 50
Positions

Birchview Capital, LP — holdings

Top 50 positions of 73, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1KLAC Kla Corp178,471+797.6%$54M25.2%
2BMY Bristol-Myers Squibb Co297,243−2.9%$17M8.0%
3LRCX Lam Research Corp35,000−2.8%$15M7.1%
4NTLA Intellia Therapeutics Inc385,900−13.4%$7M3.2%
5SLDB Solid Biosciences Inc666,196+6.4%$7M3.1%
6BDSX Biodesix Inc286,804+0.0%$6M3.0%
7STOK Stoke Therapeutics Inc178,110−15.2%$6M2.7%
8OVV Ovintiv Inc107,500+0.0%$6M2.6%
9NKTR Nektar Therapeutics81,000+161.3%$6M2.6%
10CORT Corcept Therapeutics Inc57,200+21.2%$5M2.3%
11NBIX Neurocrine Biosciences Inc27,190+0.0%$5M2.1%
12PRTA Prothena Corp Plc449,019+0.0%$4M2.1%
13ACAD Acadia Pharmaceuticals Inc171,000+0.0%$4M2.0%
14PTGX Protagonist Therapeutics Inc35,018+0.1%$4M2.0%
15CMPX Compass Therapeutics Inc1.7M+14.3%$4M1.7%
16RLMD Relmada Therapeutics Inc408,100−0.3%$3M1.3%
17ALKS Alkermes Plc50,000+0.0%$3M1.2%
18HALO Halozyme Therapeutics Inc33,251+229.2%$3M1.2%
19CLDX Celldex Therapeutics Inc New69,900−0.3%$3M1.2%
20CYTK Cytokinetics Inc30,000+0.0%$3M1.2%
21OLEMA PHARMACEUTICALS INC Olema Pharmaceuticals Inc199,000−9.1%$2M1.2%
22VERA Vera Therapeutics Inc57,758+31.3%$2M1.2%
23UTHR United Therapeutics Corp Del4,506+0.1%$2M1.1%
24ZBIO Zenas Biopharma Inc93,601+33.7%$2M1.1%
25UNIQURE NV Uniqure Nv50,697−49.7%$2M1.1%
26PACIFIC BIOSCIENCES CALIF IN Pacific Biosciences Calif In1.4M−10.0%$2M1.1%
27ABIVAX SA Abivax Sa17,000—$2M1.1%
28VIR Vir Biotechnology Inc220,000—$2M1.0%
29BIIB Biogen Inc9,000+80.0%$2M0.9%
30EQT Eqt Corp34,619+0.0%$2M0.9%
31BIOA Bioage Labs Inc69,000—$2M0.8%
32TVTX Travere Therapeutics Inc29,000−0.7%$2M0.8%
33QDEL Quidelortho Corp89,377+8.3%$2M0.7%
34AXSM Axsome Therapeutics Inc.6,000+0.0%$1M0.7%
35FHTX Foghorn Therapeutics Inc281,937+0.1%$1M0.6%
36BCYC Bicycle Therapeutics Plc313,616−32.4%$1M0.6%
37GPCR Structure Therapeutics Inc24,000−76.0%$1M0.6%
38XENE Xenon Pharmaceuticals Inc21,032+0.2%$1M0.6%
39NVO Novo-Nordisk A S24,000—$1M0.5%
40FCX Freeport Mcmoran Inc18,035−0.0%$1M0.5%
41IMNM Immunome Inc50,000+0.0%$1M0.5%
42PHVS Pharvaris N V29,847+0.0%$1M0.5%
43HROW Harrow Inc24,000+0.0%$1M0.5%
44ADAG Adagene Inc240,000—$1M0.5%
45DFTX Definium Therapeutics Inc20,000—$940,8000.4%
46SLN Silence Therapeutics Plc71,218—$781,9740.4%
47BBIO Bridgebio Pharma Inc8,741+0.6%$651,0300.3%
48FDMT 4D Molecular Therapeutics In48,505—$645,1170.3%
49URGN Urogen Pharma Ltd16,487—$606,7220.3%
50PHAT Phathom Pharmaceuticals Inc55,000−71.8%$596,7500.3%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.